Blueprint Medicines CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Blueprint Medicines announces its Q1 2025 financial results, highlighting increased product revenue driven by AYVAKIT/AYVAKYT sales and a net income of $0.5 million.
Blueprint Medicines reports third quarter 2024 financial results, showcasing revenue growth and advancements in its clinical pipeline.
Blueprint Medicines reports a net income of $39.1 million for the first half of 2024, driven by a debt extinguishment gain and strong product revenue growth, while also highlighting strategic portfolio adjustments.
Blueprint Medicines reports a strong first quarter of 2024, marked by significant product revenue growth and a substantial gain from debt extinguishment.